1. Home
  2. NRXS vs ICCC Comparison

NRXS vs ICCC Comparison

Compare NRXS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

N/A

Current Price

$5.97

Market Cap

78.9M

Sector

N/A

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.91

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRXS
ICCC
Founded
2011
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.9M
93.1M
IPO Year
2023
1995

Fundamental Metrics

Financial Performance
Metric
NRXS
ICCC
Price
$5.97
$9.91
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
89.0K
27.5K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
22.13
53.85
EPS
N/A
0.41
Revenue
$3,569,282.00
$26,493,169.00
Revenue This Year
$172.91
N/A
Revenue Next Year
$115.71
N/A
P/E Ratio
N/A
$24.44
Revenue Growth
32.89
51.64
52 Week Low
$2.21
$4.52
52 Week High
$9.33
$12.10

Technical Indicators

Market Signals
Indicator
NRXS
ICCC
Relative Strength Index (RSI) 39.42 42.02
Support Level $5.59 $9.36
Resistance Level $7.54 $10.75
Average True Range (ATR) 0.35 0.45
MACD -0.02 -0.07
Stochastic Oscillator 43.67 29.56

Price Performance

Historical Comparison
NRXS
ICCC

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: